Class G antibodies specific for benzo[a]pyrene, estradiol and progesterone in women with colorectal cancer

Abstract

The study was aimed to determine the level of class G antibodies specific to Bp, Es, Pg (IgG-Bp, IgG-Es, IgG-Pg) in patients with colorectal and breast cancers. Material and methods. The content of these antibodies in the blood serum of healthy women (n=401), patients with colorectal cancer (n=219) and patients with breast cancer (n=1469) was studied using a non-competitive enzyme immunoassay. Statistical analysis of the results was performed using the Statistica 8.0 software. Results. The levels of IgG-Bp >7 and IgG-Es>6 were higher in patients with colorectal cancer than in healthy controls (66 % vs 25 %, p<0.0001, OR=5.9 and 58 % vs s 45 %, p=0.002, OR=1.7, respectively). The individual antibody ratios of IgG-Bp/IgG-Es >1, IgG-Bp/IgG-Pg>1.5, and IgG-Es/IgG-Pg>1.5 were also higher in patients with colorectal cancer than in healthy controls (74 % vs 34 %, p<0.0001, OR=5.6; 75 % vs 28 %, p<0.0001, and 58 % vs 38 %, p<0.0001, OR=2.3, respectively). Compared to healthy controls, breast cancer patients had higher values of IgG-Bp >6 (57 % vs 33 %, p<0.0001, OR=2.7) and IgG-Es>5 (62 % vs 53 %, p=0.003, or=1.4) and ratios of IgG-Bp/IgG-Es>1 (55 % vs 34 %, p<0.0001, or=2.4), IgG-Bp/IgG-Pg>1.3 (71 % vs 36 %, p<0.0001, or=4.5) and IgG-Es/IgG-Pg>1.4 (62 % vs 44 %, p<0.0001, or=2.1). Compared to breast cancer patients, colorectal cancer patients had higher values of IgG-Bp>7 (66 % vs 50 %, p<0.0001) and the ratios of igg-Bp/IgG-Es >1 (74 % vs 55 %, p<0.0001) and IgG-Bp/IgG-Pg>1.5 (76 % vs 60 %, p<0.0001). Conclusion. IgG-Bp, IgG-Es, and IgG-Pg immunoassay could serve as a screening tool to identify population at risk of colorectal and breast cancers.

Keywords

• antibodies
• benzo[a]pyrene
• estradiol
• progesterone
• colorectal cancer
• breast cancer